Search research articles
Contact Us
Filters
Showing results (51-60 of 133) with videos related to
Page
of 14
Sort By:
Clinical Lung Cancer
|
October 17, 2022
A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement
Vasyl Nesteryuk, Omar Hamdani, Raymond Gong, et al.
Metabolites
|
October 28, 2025
Longitudinal Plasma Lipidomics Reveals Distinct Signatures Following Surgery in Patients with Glioblastoma
John Paul Aboubechara, Yin Liu, Oliver Fiehn, et al.
Cancer Treatment and Research Communications
|
May 16, 2020
A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS
Jonathan W Riess, Nadine S Jahchan, Millie Das, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 17, 2017
Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial
John V Hegde, Narek Shaverdian, Carol Felix, et al.
JTO Clinical and Research Reports
|
April 6, 2023
Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors
Thomas Yang Sun, Brandon Nguyen, Simon B Chen, et al.
Investigational New Drugs
|
September 10, 2013
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
Cheryl Ho, Angela M Davies, Randeep S Sangha, et al.
Clinical Lung Cancer
|
August 30, 2025
Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer
Fangdi Sun, Seema Nagpal, Surbhi Singhal, et al.
JTO Clinical and Research Reports
|
December 22, 2022
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
Matthew S Lara, Matthew A Gubens, Bianca Bacaltos, et al.
JCO Precision Oncology
|
July 12, 2021
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC
Michael L Cheng, Christie J Lau, Marina S D Milan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
Giulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 133) with videos related to
Sort By:
Page
of 14
Clinical Lung Cancer
|
October 17, 2022
A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement
Vasyl Nesteryuk, Omar Hamdani, Raymond Gong, et al.
Metabolites
|
October 28, 2025
Longitudinal Plasma Lipidomics Reveals Distinct Signatures Following Surgery in Patients with Glioblastoma
John Paul Aboubechara, Yin Liu, Oliver Fiehn, et al.
Cancer Treatment and Research Communications
|
May 16, 2020
A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS
Jonathan W Riess, Nadine S Jahchan, Millie Das, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 17, 2017
Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial
John V Hegde, Narek Shaverdian, Carol Felix, et al.
JTO Clinical and Research Reports
|
April 6, 2023
Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors
Thomas Yang Sun, Brandon Nguyen, Simon B Chen, et al.
Investigational New Drugs
|
September 10, 2013
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
Cheryl Ho, Angela M Davies, Randeep S Sangha, et al.
Clinical Lung Cancer
|
August 30, 2025
Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer
Fangdi Sun, Seema Nagpal, Surbhi Singhal, et al.
JTO Clinical and Research Reports
|
December 22, 2022
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
Matthew S Lara, Matthew A Gubens, Bianca Bacaltos, et al.
JCO Precision Oncology
|
July 12, 2021
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC
Michael L Cheng, Christie J Lau, Marina S D Milan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
Giulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
Page
of 14